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Abstract
Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising
treatment for patients with peritoneal carcinomatosis (PC). Our objective was to identify new prognostic factors in
patients with PC from colorectal cancer treated with this procedure.
Methods: All patients with PC from colorectal cancer treated by HIPEC from January 2000 to December 2007 were
prospectively included. The tumor extension was assessed by the Peritoneal Cancer Index (PCI) and the residual
disease was recorded using the completeness cytoreductive score (CCs). All clinical and treatment data were
computed in univariate and multivariable analyses using survival as primary end point.
Results: We carried out 51 complete procedures in 49 consecutive patients. The mean PCI was 10. The allocation
of CCs was: CC-0 = 37, CC-1 = 14. The five-year overall and progression-free survival rate were 40% and 20%,
respectively. Several prognostic factors for survival were identified by univariate analysis: PCI < 9 (P < 0.001), CC-0
vs. CC-1 (P < 0.01) and involvement of area 4 (P = 0.06), area 5 (P = 0.031), area 7 (P = 0.014), area 8 (P = 0.022),
area 10 (P < 0.0001), and area 11 (P = 0.02). Only the involvement of the distal jejunum (area 10) was significant in
the multivariable analysis (P = 0.027).
Conclusions: We demonstrated that the involvement of area 10 (distal jejunum of the PCI score) was an
independent factor associated with poor prognosis.
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Background
Peritoneal carcinomatosis (PC) is a common evolution
of digestive cancers which affects 10% of patients with
colorectal adenocarcinomas at the initial time of diagno-
sis and 25% of patients with recurrent disease [1]. More-
over, as reported in the French EVOCAPE 1 Study, PC
is traditionally associated with a poor prognosis: for col-
orectal cancer patients, mean and median overall survi-
val were 6.9 and 5.2 months, respectively [2].
For two decades, the development of a new concept
involving cytoreductive surgery and hyperthermic intra-
peritoneal chemotherapy (HIPEC) has demonstrated
promising results. One of the first publications, Sugarba-
ker et al. [3] reported a three-year survival rate of 61%.
Later, other phase II studies became available showing a
median survival lasting from 13 to 63 months [4-8]. A
single randomized trial comparing cytoreduction fol-
lowed by HIPEC and adjuvant systemic chemotherapy
to systemic chemotherapy demonstrated the superiority
of the combined treatment [9]. All these results suggest
that this combined surgical treatment should be consid-
ered as the current standard treatment for PC from col-
orectal origin.
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cations including variation of chemotherapy regimen,
techniques of hyperthermia or duration of the proce-
dure, two prognostic factor are currently identified [10]:
the extent of disease before surgery, usually scored by
the peritoneal cancer index (PCI), and the quality of the
surgical cytoreduction, measured by the completness of
cytoreduction score (CCs) [11]. So, only patients with
limited PC and complete cytoreduction will really bene-
fit from cytoreductive surgery and HIPEC.
The aim of our study was to identify new prognostic
factors in patients treated by cytoredutive surgery and
HIPEC for PC from colorectal origin at Nice Peritoneal
Cancer Center. Thus, above all, we assessed the prog-
nostic impact of PC involvement by area.
Methods
From January 2000 to December 2007, all patients with
resectable PC from colorectal cancer underwent cytore-
ductive surgery followed by HIPEC at Nice Peritoneal
Cancer Center. All patients were included in a prospec-
tive database, and gave their signed informed consent.
This study was approved by our institutional review
committee.
Inclusion criteria
All primary cancers were confirmed by a biopsy.
In order to evaluate the extent of the disease, all
patients underwent preoperative investigations which
included thoracic, abdominal and pelvic computed
tomography (CT) with oral and intravenous contrast
agents. From 2004, positron emission tomography was
additionally performed.
Anaesthetic evaluation, echocardiography, and spiro-
metry were performed for all patients.
Patients were then selected preoperatively according
to the following criteria: (1) < 75 years old and good
general status (World Health Organization (WHO) Per-
formance Status < 2); (2) PC from colorectal carcinoma,
but non-appendiceal; (3) no extra-abdominal disease; (4)
no multiple, diffuse, and huge-tumor peritoneal deposits
on the CT scan; (5) no evidence of intestinal obstruction
or involvement; (6) no evidence of biliary or ureteral
obstruction; and (7) no massive and total abdominal
involvement on clinical examination.
For borderline cases, a laparoscopy was performed
preoperatively.
Modalities of the combined treatment
During the laparotomy, the extent of the PC was calcu-
lated for each patient using the PCI, as described by
Sugarbaker et al. [11]. This score links the tumor loca-
tion (areas 0 to 8 for the abdominal cavity and 9 to 12
for the small bowel) with the lesion size (LS0: no tumor
deposit, to LS3: tumor thickness > 5 cm). So, the PCI
can range from 1 to 39 (Figure 1). If the PC seemed to
be resectable, a cytoreductive surgery was done with
resection or destruction by electrovaporation of all the
macroscopically detectable peritoneal disease. After this
surgical procedure, the CCs was evaluated for each
patient. CC-0 score indicated that no tumor was visible
in the peritoneal cavity; CC-1 indicated a residual tumor
< 2.5 mm; CC-2 indicated a residual tumor between 2.5
mm and 2.5 cm; CC-3 indicated a residual tumor > 2.5
cm or a confluence of nodules [11].
Only patients scoring CC-0 or CC-1, were considered
to have a complete cytoreduction and were eligible for
the HIPEC procedure. Mitomycin C was administrated
intraperitoneally in the open abdominal cavity using the
coliseum technique with a Thompson self-retaining
retractor [12]. The dose was 12.5 mg/m
2 for men and
10 mg/m
2 for women, in 2 L/m
2 of 1.5% dextrose peri-
toneal dialysis solution. A heat exchange kept the intra-
peritoneal temperature at 42°C for 90 min.
Follow-up and study methods
All patients were followed every 6 months with a clinical
examination, thoracic, and abdominopelvic CT scan, and
carcinoembryonic antigen measurement. All data were
collected in a prospective database.
The statistical analysis used overall survival as the pri-
mary endpoint.
For categorical variables, the c
2 test or Fisher’se x a c t
test, when appropriate, was used. Continuous variables
were compared with the student t-test.
Survival was defined from the time of the surgical pro-
cedure. Survival analysis was performed using the
Kaplan-Meier method, and compared using the log-rank
test. No patient was excluded from survival analysis.
A multivariate analysis using a Cox-regression model
was done to identify independent prognostic factors for
survival.
P values of less than 0.05 were considered significant.
Statistical analysis was performed using SPSS v 16 for
Windows (SPSS, Chicago, Illinois, USA).
Results
Descriptive data
From January 2000 to December 2007, 51 procedures
(HIPEC) in 49 consecutive patients were performed.
There were 30 women (61.2%) and 19 men (38.8%). The
mean age was 52.7 ± 11 years (range: 32-75). The loca-
tion of the tumor was colonic in 41 cases (83.7%) and
rectal in all the others cases. At initial staging, 22
patients (44.9%) had positive lymph nodes; tumor grade
was poorly differentiated for six patients (12.2%), moder-
ately differentiated for 35 patients (71.4%) and well dif-
ferentiated for eight patients (16.3%). The time between
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cedure was 20 ± 9 months (range: 1-87). Thirty-seven
(72.5%) patients received neoadjuvant chemotherapy
(with a mean of 1.2 lines (range: 0-4)). The mean PCI
was 10 ± 6.2 (range: 1-22). The number of areas
involved was 5 ± 3.3 (range: 1-13). Thirty-seven proce-
dures (72.5%) were considered as CC-0 cytoreduction;
12 procedures (23.5%) were CC-1 cytoreduction. The
CCs was significantly correlated with the PCI: median
PCI was 7 in the CC-0 group versus 16 in the CC-1
group (P < 0.0001). During the cytoreductive surgery,
there were 3 ± 1.6 visceral resections (range: 0-7).
Among the 31 patients (61.8%) with small bowel invol-
vement, 19 (61.3%) had a small bowel resection and 12
(23.5%) underwent destruction of the peritoneal nodules
by electrovaporation. The operative time was 474 ± 127
min (range: 180-780). The mean unit of blood transfu-
sion was 1.3 ± 1.6 (range: 0-7).
There was no mortality. Ten patients (20.5%) had a
complication which required specific medical or surgical
treatment (grade III and IV of Clavien). These adverse
events included digestive fistula (n = 2), biliary leak (n =
2), bleeding (n = 1), short bowel with diarrhea (n =2 ) ,
subphrenic abcess (n = 1), and thrombocytopenia (n =
1). The length of hospital stay was 18.6 ± 10 days
(range: 7-52).
Survival data
The mean follow-up was 27 ± 8 months (range 9-83).
The median overall survival was 51 months and the
median disease-free survival was 34.5 months (Figure
2A and 2B).
In univariate analysis, the extent of the peritoneal car-
cinomatosis mesured by the PCI (P <0 . 0 1 )a n dt h e
quality of the cytoreduction measured by the CCs (P <
0.01) were significant prognostic factors (Figures 3 and
4). Moreover, the involvement of the areas 4, 5, 7, 8, 10,
and 11 was also associated with median survival in uni-
variate analysis (Table 1). Age (P = 0.87), sex (P = 0.48),
preoperative chemotherapy (P = 0.29), grade of the pri-
mary tumor (P = 0.13), and nodal status (P = 0.85) were
not associated with median survival in univariate
analysis.
In multivariate analysis by Cox model represented in
Table 2, the involvement of area 10 was the only signifi-
cant prognostic factor (HR = 21.81 CI 95 (1.42-334.5) P
= 0.027).
Discussion
For many years, PC was considered an incurable disease.
The development of cytoreductive surgery followed by
HIPEC has totally changed the course of this condition,
with median survival reported lasting from 13 to 63
months in selected cases [4-8]. In this study, the overall
median survival was 51 months, which supports the
effectiveness of this technique. Currently, the objective
is to optimize the selection of patients who will benefit
from this aggressive approach. In this context, many
prognostic factors have been described to predict the
outcome of HIPEC procedures.
The CCs is usually reported as the most important
factor in predicting outcome. Survival results following
CC-2 cytoreduction are very poor, and HIPEC should
not be performed in this situation [13,14]. In the
study reported by Glehen [5], the five-year survival
rate was 31% for CC-0 patients. These results were
significantly better than CC-1 (15%) or CC-2 (no
patients alive) conditions. In univariate analysis, our
Figure 1 Description of the PCI (Peritoneal Cancer Index). The PCI provides an assessment of tumor volume and distribution in the
abdominopelvic cavity (nine quadrants) and the small bowel (four regions).
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ian survival of 52 months for CC-0 vs 35 months for
CC-1 patients (P < 0.01). Nevertheless, this prognostic
factor was not demonstrable in our multivariate
analysis probably because we do not perform HIPEC
for CC-2 patients.
In addition, the extent of the peritoneal carcinomato-
s i sm e a s u r e db yt h eP C Ii sr e p o r t e da sap r o g n o s t i c
Figure 2 Survival results in 49 patients after HIPEC (hyperthermic intraperitoneal chemotherapy) for colorectal peritoneal
carcinomatosis. Overall survival (OS). Disease free survival (DFS).
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cutoff associated with a poor prognosis. This limit
ranges between 10 and 20 depending on the authors
[15-17]. Our study confirmed in univariate analysis that
the extent of disease before surgery is a prognostic fac-
tor with a threshold of 9, under which patients have an
excellent prognosis. Moreover, as described in Figure 2,
the CCs was significantly correlated with the PCI, justi-
fying that these two factors are not highlighted in multi-
variate analysis. Finally, PCI is a score calculated from
qualitative and quantitative data. However, in published
series, this score is considered as purely quantitative
data which induce interpretation bias. Therefore, we felt
it was important to assess only the impact of qualitative
data, by studying the location of PC. Our results were
very interesting since we have shown for the first time
that the involvement of the small bowel, and especially
in area 10, was an independent prognostic factor of
survival.
The involvement of the small bowel is a well-known
cause of incomplete surgical cytoreduction, especially
when the disease is located at the junction between the
small bowel and its own mesenterium [18]. Neverthe-
less, even when the surgical cytoreduction is complete,
this spread appears to be an independent prognostic fac-
tor. The invasion of the rest of the small bowel (areas 9,
11, and 12) did not emerge in this study, and may be
due to lack of power.
Figure 3 Kaplan-Meir survival curves for patients with PCI (Peritoneal Cancer Index) > 9 or < 9.I nu n i v a r i a t ea n a l y s i s ,t h eP C Ii sa
prognostic factor (Log rank: P < 0.001).
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tively the precise extension of the CP, especially for the
small bowel. CT scan is the most used imaging method,
but in fact, it is inaccurate and its impact on the man-
agement of patients is modest [19]. Laparoscopy may
supplement imaging modalities, but in our practice, it is
sometimes difficult to perform (iterative surgery, adhe-
sions) and it is not always accurate (assessment of the
retroperitoneal space and the posterior segments of the
liver). However, this tool should not be disregarded, and
its use can be discussed as part of a multidisciplinary
approach if diffuse or massive small bowel involvement
is suspected preoperatively [20].
Lymphatic drainage of the peritoneal cavity is ensured
through the so-called stomata which facilitate communi-
cation between the abdominal cavity, and the
Figure 4 Kaplan-Meir survival curves for patients Cc0 or Cc1 (Cytoreductive score 0 or 1). In univariate analysis, the CCs is a prognostic
factor (Log rank: P < 0.01).
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mata of the visceral and parietal peritoneum are very
heterogeneous, suggesting different functional implica-
tions. The presence of openings in the mesentery
explains an increased lymphatic permeability [22]. This
could lead to a lymph node extension, and explain the
poor prognosis associated with the invasion of the small
bowel.
In this context, lymph node involvement is also a
prognostic factor reported in some series [23]. This
issue has not been found in our study. The lymphatic
extension reflects systemic spread of disease that cannot
be treated with a locoregional therapeutic approach.
Thus, the involvement of the small bowel, even in the
absence of lymph node metastases, could suggest addi-
tional treatment with systemic chemotherapy.
Other, predictors are reported in the literature such as
the differentiation grade or the location of the primary
tumor [16]. These factors appear less strong, and were
not found in our series.
Conclusion
We have identified several prognostic factors by univari-
ate analysis, especially the PCI, the CCs and some areas
of the peritoneal cavity. But most interesting is the fact
that only the invasion of the distal jejunum (area 10) is
independently associated with a poor prognosis. It will
be difficult to assess this invasion preoperatively because
conventional imaging techniques underestimate the
extent of intraperitoneal spread. Nevertheless, in case of
small bowel invasion confirmed at surgery, additional
treatment with systemic chemotherapy could be
proposed.
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